Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Javed Butler et al.|New England Journal of Medicine|2021Cited by 4.6k
Dabigatran versus Warfarin in Patients with Mechanical Heart ValvesJohn W. Eikelboom, Frans Van de Werf, A. Pieter Kappetein et al.|New England Journal of Medicine|2013Cited by 1.5k
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaı̈ez Zannad, Milton Packer, João Pedro Ferreira et al.|The Lancet|2020Cited by 1.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Christiane E. Angermann et al.|Nature Medicine|2022Cited by 889